Genetic testing: A powerful tool in the fight against cardiovascular diseases

Cardiovascular diseases and their risk factors

Various diseases affecting the heart and its blood vessels are referred to as CVD, with the most common ones being heart failure, coronary heart disease, myocardial infarction (heart attack), hypertension, and cerebrovascular disease (including stroke) []. Until now, the risk of developing a CVD was calculated using lifestyle factors such as high body mass index (BMI), smoking, physical inactivity, and high blood cholesterol [].

While the aforementioned risk factors play significant roles, in recent years, emphasis has also shifted towards hereditary factors, as research has shown that people can inherit genetic changes – known as mutations – that could potentially result in a compromised cardiovascular system [].

Genes provide instructions for our bodies, determining everything from our eye colour to our risk of developing certain diseases. In the case of CVD, genetic variations can impact various health functions of the heart, including:

• Cholesterol levels: Genes influence how our bodies produce and regulate cholesterol, a substance essential for cell function that is harmful in excess levels as it could lead to the development of atherosclerosis and subsequently heart attacks, amongst other cardiovascular complications.
• Blood pressure: Genetic mutations can contribute to high blood pressure, a major risk factor for heart disease and stroke.
• Blood clotting: Genetic mutations in genes involved in blood clotting can increase the risk of blood clots forming, which can lead to heart attacks and strokes.
• Heart muscle function: Genetic mutations can affect the structure and function of the heart muscle, leading to conditions like cardiomyopathy.
• Heart rhythm: Genetic mutations can influence heart rhythm by altering the structure and function of the heart’s electrical system, leading to conditions like and .

The role of genetic testing in cardiovascular disease

Genetic testing has emerged as a powerful tool for assessing an individual’s risk of developing CVDs and guiding preventive measures. This process involves analysing a person’s DNA to identify specific genetic mutations that may predispose them to heart attacks, strokes, or other cardiovascular conditions. It’s important to note that genetic mutations are present from birth, but their symptoms may not manifest until later in life. Therefore, early detection through genetic testing is crucial, as individuals diagnosed at an early stage have a better chance of managing their condition through therapies or lifestyle modifications. This proactive approach can significantly reduce the risk of serious complications and improve overall cardiovascular health and patient outcomes.

In addition, several reputable organisations and societies, including the and the , recommend genetic screening as a valuable tool for assessing cardiovascular risk []. As genetic testing technology advances, it is likely to play an even greater role in preventing CVDs and improving public health.

Genetic counselling plays a crucial role in the genetic testing process. Before testing, a genetic counsellor will go through the patient’s family history and explain the test’s potential benefits and limitations, discuss the results’ implications, and address any concerns or questions. After the test, the counsellor can help interpret the results, discuss the potential impact on the individual’s health and their family, and provide guidance on the next steps, such as lifestyle modifications or medical interventions.

The benefits of cardiovascular genetic testing

The potential benefits of genetic testing for cardiovascular health are substantial. By identifying high-risk individuals, healthcare providers can implement targeted preventive strategies, such as regular check-ups, medication, and lifestyle modification. This proactive approach can help prevent heart attacks, strokes, or other catastrophic events.

Key benefits include:

• Early risk identification: Genetic testing can identify individuals with a higher risk of developing heart disease early in life, even before symptoms appear. This early awareness allows proactive measures to be taken to reduce risk, such as early lifestyle modifications or preventive therapies.
• Personalised risk assessment: By analysing an individual’s genetic makeup, healthcare providers can refine traditional risk assessment tools, providing a more accurate and personalised estimate of their risk for heart disease.
• Tailored prevention strategies: Genetic insight can help healthcare providers recommend specific lifestyle modifications, medications, or screening tests tailored to an individual’s genetic risk factors. This personalised approach can lead to more effective prevention strategies.
• Identify at-risk family members: Depending on the mutation found, healthcare providers can suggest genetic testing for other family members who might be at risk of having the same mutation.
• Family planning: For individuals with a family history of heart disease, genetic testing can help them make informed decisions about family planning. Understanding their genetic risk can help them plan for potential health challenges and make choices that minimise the risk of passing on these conditions to their children.

Personalised risk stratification and disease management

Another great advantage of cardiovascular genetic testing is personalised disease management based on genetic insights. Depending on specific genetic mutations identified, doctors can guide a more personalised instead of a generalised treatment plan. For example, in the case of , genetic testing can provide a more accurate prognosis and risk stratification. Mutations in the MYPBC3 gene are associated with significantly better prognosis in comparison with mutations in the MYH7, TNNT2, TNNI3, and TPM1 genes [, ].

For (DCM), the identification of specific mutations has been proven pivotal for accurate prognosis and clinical management. Mutations in LMNA, SCN5A, FLNC, RBM20, and PLN genes are associated with a high risk of life-threatening arrhythmias while mutations in the LMNA gene are associated with high morbidity and mortality. Beyond an accurate prognosis, genetic testing can also provide valuable information for medical decision-making, especially when it comes to inserting an implantable cardioverter defibrillator (ICD), the main preventive therapy for patients with DCM. For example, patients with FLNC and PLN mutations should be given an ICD, instead of taking standard medication for DCM, as they have a higher risk of sudden cardiac death [].

The future of genetic testing for cardiovascular disease

Genetic testing for CVD is poised to revolutionise the way we approach cardiovascular health. As our understanding of the intricate interplay between genetics and cardiac function deepens, genetic testing is emerging as a powerful tool in preventing and managing CVDs. Additionally, the rapidly evolving knowledge due to genetics can lead to novel therapeutic methods that target specific genetic pathways, resulting in an even better prognosis for a patient.

Conclusion

Genetic testing is an invaluable tool for assessing an individual’s risk for cardiovascular disease. By identifying genetic mutations that contribute to heart disease, individuals can take proactive steps to reduce their risk and improve their cardiovascular health. As genetic testing becomes more affordable and widely available, it is likely to become an integral part of routine cardiovascular care. By harnessing the power of genetics, we can move towards a future where CVDs are prevented, detected early, and effectively treated. However, it’s important to remember that genetic testing is just one piece of the puzzle. A healthy lifestyle, including a balanced diet, regular exercise, and avoiding smoking, remains crucial for preventing heart disease.